A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Inclusion Criteria: 1. Ability to understand and the willingness to sign a written informed consent document； 2. Age ≥18 years old; 3. Histologically or cytologically confirmed prostate adenocarcinoma; 4. Candidate for androgen deprivation therapy (ADT) for the management of hormone-sensitive prostate cancer； 5. Appropriate serum testosterone and serum PSA concentration at screening as specified in the protocol； 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1; 7. Adequate organ performance based on laboratory blood tests; 8. Agree to use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: 1. Previously received gonadotropin-releasing hormone analogues (GnRH-a) for more than 12 months total duration (if GnRH-a was received for 12 months or less, then that GnRH-a must have been completed washout period prior to the first dose of study drug). 2. Patients who have received chemotherapy for prostate cancer; 3. History of surgical castration; 4. Received Abiraterone acetate with 3 months prior to the first dose of study drug; 5. Receieved molecular target therapy, immunotherapy, androgen receptor blockade, 5-alpha reductase inhibitors, estrogen, and other investigational compound with 4 weeks prior to the first dose of study drug; 6. Patients with known or suspected brain metastasis； 7. Diagnosis or treatment for another systemic malignancy within 5 years before study treatment initiation; 8. Patients with uncontrolled and clinically significant hypertension and diabetes; 9. Known hypersensitivity to SHR7280, SHR7280 excipients,； 10. History of immunodeficiency (including HIV infection) or organ transplantation; 11. Known active hepatitis B or C infection; 12. Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.